BIIB Jan 2023 310.000 put
| Previous close | 119.32 |
| Open | 119.32 |
| Bid | 92.00 |
| Ask | 98.80 |
| Strike | 310.00 |
| Expiry date | 2023-01-20 |
| Day's range | 119.32 - 119.32 |
| Contract range | N/A |
| Volume | |
| Open interest | 70 |
- Motley Fool
Is This Biotech Stock a Bad News Buy?
Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period. The drugmaker has encountered many headwinds related to its controversial Alzheimer's disease drug, Aduhelm. Recapping the entire Aduhelm saga would take far more space than we have here.
- Zacks
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
- Business Wire
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,
